...
首页> 外文期刊>BMC Pregnancy and Childbirth >Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
【24h】

Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)

机译:孕中期早产胎膜早破(PPROM):预期处理或羊膜腔灌注可改善围产期结局(PPROMEXIL – III试验)

获取原文
           

摘要

Background Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high. Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lung development. Repeated transabdominal amnioinfusion with the objective to alleviate oligohydramnios might prevent this complication and might improve neonatal outcome. Methods/Design Women with PPROM and persisting oligohydramnios between 16 and 24?weeks gestational age will be asked to participate in a multi-centre randomised controlled trial. Intervention: random allocation to (repeated) abdominal amnioinfusion (intervention) or expectant management (control). The primary outcome is perinatal mortality. Secondary outcomes are lethal pulmonary hypoplasia, non-lethal pulmonary hypoplasia, survival till discharge from NICU, neonatal mortality, chronic lung disease (CLD), number of days ventilatory support, necrotizing enterocolitis (NEC), periventricular leucomalacia (PVL) more than grade I, severe intraventricular hemorrhage (IVH) more than grade II, proven neonatal sepsis, gestational age at delivery, time to delivery, indication for delivery, successful amnioinfusion, placental abruption, cord prolapse, chorioamnionitis, fetal trauma due to puncture. The study will be evaluated according to intention to treat. To show a decrease in perinatal mortality from 70% to 35%, we need to randomise two groups of 28 women (two sided test, β-error 0.2 and α-error 0.05). Discussion This study will answer the question if (repeated) abdominal amnioinfusion after midtrimester PPROM with associated oligohydramnios improves perinatal survival and prevents pulmonary hypoplasia and other neonatal morbidities. Moreover, it will assess the risks associated with this procedure. Trial registration NTR3492 Dutch Trial Register ( http://www.trialregister.nl webcite ).
机译:背景早孕中期早产胎膜破裂(PPROM)后出生的婴儿有发生新生儿肺发育不良的危险。这种并发症后的围产期死亡率和发病率很高。 PPROM之后的妊娠中期羊水过少被认为会导致肺发育延迟。以减轻羊水过少为目标的反复经腹羊膜腔灌注可以预防这种并发症并可能改善新生儿结局。方法/设计要求具有PPROM且持续羊水过少的孕妇在16至24周胎龄之间参加多中心随机对照试验。干预:随机分配(重复)腹部羊膜腔灌注(干预)或预期治疗(对照)。主要结局是围产期死亡率。次要结局为致命性肺发育不全,非致命性肺发育不全,重症监护病房(NICU)直至出院的存活率,新生儿死亡率,慢性肺病(CLD),通气支持天数,坏死性小肠结肠炎(NEC),脑室白细胞软化症(PVL)超过I级,超过II级的严重脑室内出血(IVH),已证实的新生儿败血症,分娩时的胎龄,分娩时间,分娩指征,成功的羊膜腔灌注,胎盘早剥,脐带脱垂,绒毛膜羊膜炎,因穿刺引起的胎儿创伤。该研究将根据治疗意图进行评估。为了将围产期死亡率从70%降低到35%,我们需要将两组28名妇女随机分组(双面检验,β误差为0.2,α误差为0.05)。讨论本研究将回答以下问题:妊娠中期PPROM术后(重复)腹腔羊膜腔灌注与羊水过少相关联,是否可以改善围产期生存并预防肺发育不全和其他新生儿疾病。此外,它将评估与此程序相关的风险。试用注册NTR3492荷兰试用注册(http://www.trialregister.nl webcite)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号